Sonoma Pharmaceuticals (SNOA)
(Real Time Quote from BATS)
$0.15 USD
-0.01 (-5.66%)
Updated Apr 29, 2024 11:02 AM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Sonoma Pharmaceuticals, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 7 | 4 | 4 |
Receivables | NA | 3 | 2 | 3 | 4 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 3 | 3 | 2 |
Other Current Assets | NA | 5 | 4 | 3 | 2 |
Total Current Assets | NA | 14 | 16 | 13 | 12 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 1 | 1 | 1 | 1 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 16 | 19 | 15 | 15 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 1 | 1 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 1 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 0 | 0 |
Total Current Liabilities | NA | 4 | 6 | 4 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 3 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 8 | 10 | 10 | 6 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 201 | 197 | 189 | 187 |
Retained Earnings | NA | -190 | -184 | -179 | -172 |
Other Equity | NA | -3 | -4 | -5 | -6 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 8 | 9 | 5 | 9 |
Total Liabilities & Shareholder's Equity | NA | 16 | 19 | 15 | 15 |
Total Common Equity | 0 | 8 | 9 | 5 | 9 |
Shares Outstanding | 15.60 | 4.60 | 3.10 | 2.00 | 1.70 |
Book Value Per Share | 0.00 | 1.73 | 2.81 | 2.68 | 5.12 |
Fiscal Year End for Sonoma Pharmaceuticals, Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2 | 2 | 4 | 4 |
Receivables | NA | 3 | 2 | 2 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 3 | 3 | 3 |
Other Current Assets | NA | 4 | 5 | 5 | 5 |
Total Current Assets | NA | 13 | 12 | 14 | 14 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 1 | 1 | 1 | 1 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 15 | 14 | 16 | 16 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 3 | 4 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 8 | 8 | 9 | 8 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 203 | 201 | 201 | 201 |
Retained Earnings | NA | -193 | -192 | -191 | -190 |
Other Equity | NA | -3 | -3 | -3 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 7 | 6 | 7 | 8 |
Total Liabilities & Shareholder's Equity | NA | 15 | 14 | 16 | 16 |
Total Common Equity | 0 | 7 | 6 | 7 | 8 |
Shares Outstanding | 15.60 | 13.60 | 5.10 | 5.10 | 4.60 |
Book Value Per Share | 0.00 | 0.49 | 1.11 | 1.42 | 1.73 |